Late results of a trial of hyperbaric oxygen and radiotherapy in head and neck cancer: a rationale for hypoxic cell sensitizers?
104 patients with head and neck cancer were entered into a prospective controlled trial of radiotherapy in hyperbaric oxygen (HBO). The trial compared 10 fractions of radiotherapy in HBO with 30 fractions of radiotherapy in air. Survival and local control rates were significantly higher in the HBO group. No difference in normal tissue effects were detected. The greatest advantage of HBO was seen in the less advanced tumors.